International Journal of Clinical Biochemistry and Research

Print ISSN: 2394-6369

Online ISSN: 2394-6377

CODEN : IJCBK6

International Journal of Clinical Biochemistry and Research (IJCBR) open access, peer-reviewed quarterly journal publishing since 2014 and is published under auspices of the Innovative Education and Scientific Research Foundation (IESRF), aim to uplift researchers, scholars, academicians, and professionals in all academic and scientific disciplines. IESRF is dedicated to the transfer of technology and research by publishing scientific journals, research content, providing professional’s membership, and conducting conferences, seminars, and award more...

Article type

Short Communication


Article page

255- 257


Authors Details

Abhinav Manish*


Article Metrics


View Article As

 


Downlaod Files

   






Article statistics

Viewed: 434

PDF Downloaded: 201


Diabetes mellitus: A lifestyle disorder


Short Communication

Author Details : Abhinav Manish*

Volume : 10, Issue : 3, Year : 2023

Article Page : 255-257

https://doi.org/10.18231/j.ijcbr.2023.045



Suggest article by email

Get Permission

Abstract

Diabetes mellitus is a chronic metabolic disorder characterized by elevated blood glucose levels, resulting from either insufficient insulin production or the body's inability to effectively utilize insulin. This condition has become a global health concern, with an increasing prevalence worldwide. This review article aims to provide an overview of diabetes mellitus, its diagnostic criteria, and recent updates in management, complications, and a discussion on its implications for public health.


How to cite : Manish A, Diabetes mellitus: A lifestyle disorder. Int J Clin Biochem Res 2023;10(3):255-257

This is an Open Access (OA) journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.